9,662 Results

Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines

 Added 23 hours ago

Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...

United Therapeutics licenses global rights from Arena Pharma to ralinepag for the treatment of pulmonary arterial hypertension.

 Added 23 hours ago

Arena Pharmaceuticals, Inc. and United Therapeutics Corporation announced that the companies have entered into a global license agreement for Arena's...

FDA grants De Novo clearance for Innovo device for the treatment of stress urinary incontinence.- Atlantic Therapeutics.

 Added 23 hours ago

Atlantic Therapeutics, a global manufacturer of innovative, garment-based pelvic floor muscle strengthening and nerve stimulation products, announced that the FDA...

EU approves Cabometyx for liver cancer.- Ipsen + Exelixis.

 Added 23 hours ago

Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for Cabometyx (cabozantinib) tablets as a monotherapy...

TCH-003 study of Nerivio Migra meets primary endpoint in migraine control.- Theranica.

 Added 23 hours ago

At the annual headache symposium of the American Headache Society, Theranica announces the results of TCH-003, a pivotal study of...

FDA Advisory Committees recommended approval of abuse deterrent reformulation of Roxicodone by the nasal route to manage severe pain.- SpecGx / Mallinckrodt.

 Added 23 hours ago

SpecGx LLC , a subsidiary of Mallinckrodt plc, that operates its Specialty Generics business, announced that, in a joint meeting,...

FDA approves extension of approval of Oralair in grass allergy.- Stallergenes Greer.

 Added 1 day ago

Stallergenes Greer announced that it has received approval from the FDA for the extension of the indication for Oralair (Sweet...

FDA accepts rolling submission of V 920 in Ebola Zaire disease.- Merck Inc.

 Added 1 day ago

Merck Inc. announced that it has started the submission of a rolling Biologics License Application (BLA) to the FDA for...

In phase III KEYNOTE-181 trial, Keytruda meets primary endpoint in oesophageal cancer.- Merck Inc.

 Added 1 day ago

Merck Inc announced that the Phase III KEYNOTE-181 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy in the second-line...

TAPPAS phase III trial shows ApoStream effective in capturing tumour cells in angiosarcoma.- Precision for Medicine.

 Added 1 day ago

Precision for Medicine and TRACON Pharmaceuticals announced the publication of biomarker results from the TAPPAS phase III clinical trial that...

Load more